The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,746.00
Bid: 1,747.00
Ask: 1,749.00
Change: 21.00 (1.22%)
Spread: 2.00 (0.114%)
Open: 1,736.00
High: 1,753.00
Low: 1,734.00
Prev. Close: 1,725.00
IMI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

4 May 2023 07:00

RNS Number : 3271Y
IMI PLC
04 May 2023
 

4 May 2023

Strong organic growth and margin improvement in all three divisions

Full year EPS guidance increased to 112p - 117p

IMI, the specialist engineering company, issues the following Interim Management Statement which covers results for the first quarter from 1 January to 31 March 2023.

Roy Twite, Chief Executive, commented:

"Our purpose-led strategy, Breakthrough Engineering for a better world, continues to drive sustainable, profitable growth. Our solutions help our customers become safer, more sustainable and more productive and we are continuously creating value through a focus on customer satisfaction, market-led innovation and complexity reduction. These actions have allowed us to deliver a ninth consecutive quarter of organic growth and improved margins in all three divisions."

"Following a strong first quarter performance including further momentum in the IMI Critical order intake and continued resilience in the lead indicators for IMI Precision, based on current market conditions, we are upgrading our EPS guidance for the full year to 112p to 117p. We remain confident in delivering our growth targets and the 20% operating margin target, through the cycle over time."

Strong first quarter performance

First quarter Group organic revenue was up 8% compared to the same period last year and 16% higher on an adjusted basis. All three divisions improved margins when compared to the first quarter in 2022.

Integration of our recent acquisitions is progressing well, unlocking new opportunities for growth and delivering synergies in line with our business cases.

Our restructuring programmes remain on track to deliver £20m of benefits for the full year, £13m of benefits in 2024 and £9m in 2025, with no changes to expected delivery costs.

Growth delivered across key segments

IMI Precision organic revenue grew 4% in the first quarter and 12% on an adjusted basis. Industrial Automation delivered organic revenues 3% higher than the same period last year. Life Sciences delivered organic growth of 2% and Transportation was up 10% on an organic basis.

IMI Critical organic order intake in the period was up 50% on prior year, including a £26m order within our Marine sector which covers deliveries in the coming years. Aftermarket orders grew 47% organically in the period with strong growth in Refining & Petrochemical, Oil & Gas and Power. New Construction orders were 55% higher on an organic basis, largely reflecting increased Oil & Gas activity and the large Marine order. IMI Critical's order book at the end of the first quarter was 36% higher than the same period last year. Organic revenue in the first quarter was up 13% compared to the corresponding period in 2022, and 16% on an adjusted basis.

IMI Hydronic revenue in the first quarter was 12% higher on an organic basis, and 25% higher on an adjusted basis, when compared to the first quarter of last year driven by demand for our solutions that support energy efficiency.

Exchange rates

If average exchange rates as at 14 April 2023 of US$1.23 and €1.13 remain constant for the remainder of the year, we continue to expect a positive tailwind on both revenue and adjusted operating profit of 2% in the 2023 full year when compared to 2022.

Outlook

Following a strong first quarter performance, based on current market conditions, we now expect 2023 full year adjusted EPS to be in the range of 112p to 117p.

We continue to expect IMI Critical and IMI Hydronic 2023 organic revenues and margins to be higher than 2022. Based on the latest market indicators, we now expect that IMI Precision's 2023 organic revenue will be broadly in line with 2022, with margins higher than 2022.

We remain confident in delivering our growth targets and the 20% operating margin target, through the cycle over time.

Interim results

 

IMI will issue its interim results announcement in respect of the six months ending 30 June 2023 on 28 July 2023.

 

Enquiries

Luke Grant

IMI

Tel: +44 (0)7866 148 374

Matt Denham

Headland PR

Tel: +44 (0)7551 825 496

A conference call for analysts and investors will be held at 08:00 BST today to discuss this statement. To access the call, please register using the link:

https://www.netroadshow.com/events/login?show=5b69489b&confId=50046

 

Notes

IMI plc is a specialist engineering company operating in fluid and motion control markets. We combine our deep engineering knowledge with strong applications expertise to develop solutions for the most acute industry problems. We help our customers become safer, more sustainable and more productive. IMI employs around 10,000 people, has manufacturing facilities in 19 countries and operates a global service network. The Company is listed on the London Stock Exchange and is a constituent of the FTSE4Good Index. Further information is available at www.imiplc.com.

 

References to adjusted figures reflect figures as reported to management and do not include the impact of adjusting items. References to organic changes are on a constant currency basis and exclude disposals and acquisitions.

 

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF751R30.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFQXLFBXELBBBD
Date   Source Headline
12th Apr 20241:49 pmRNSDirector/PDMR Shareholding
10th Apr 20241:42 pmRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
28th Mar 20249:11 amRNSAnnual Financial Report
27th Mar 20244:48 pmRNSDirector/PDMR Shareholding
20th Mar 202411:37 amRNSDirector/PDMR Shareholding
14th Mar 20248:58 amRNSRetail Investor Webinar
13th Mar 20241:58 pmRNSDirector/PDMR Shareholding
1st Mar 20241:58 pmRNSTotal Voting Rights
1st Mar 20241:57 pmRNSDirector Declaration
1st Mar 20247:00 amRNSPreliminary Results
29th Feb 202410:09 amRNSDirectorate Change
27th Feb 20248:54 amRNSHolding(s) in Company
14th Feb 202411:35 amRNSDirector/PDMR Shareholding
1st Feb 202411:28 amRNSTotal Voting Rights
30th Jan 202411:02 amRNSDirectorate Change
10th Jan 20241:01 pmRNSDirector/PDMR Shareholding
2nd Jan 202411:35 amRNSBlock listing Interim Review
2nd Jan 202411:04 amRNSTotal Voting Rights
19th Dec 20239:55 amRNSDirector/PDMR Shareholding
13th Dec 20233:41 pmRNSDirector/PDMR Shareholding
5th Dec 20239:28 amRNSDirector Declaration
1st Dec 20231:30 pmRNSTotal Voting Rights
15th Nov 20231:42 pmRNSDirector/PDMR Shareholding
9th Nov 20237:01 amRNSHistorical Financial Information
9th Nov 20237:00 amRNSInterim Management Statement
1st Nov 202312:42 pmRNSTotal Voting Rights
11th Oct 20233:20 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:19 pmRNSTotal Voting Rights
13th Sep 20233:32 pmRNSDirector/PDMR Shareholding
1st Sep 202311:29 amRNSTotal Voting Rights
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
10th Aug 20234:38 pmRNSDirector/PDMR Shareholding
9th Aug 20232:34 pmRNSDirector/PDMR Shareholding
1st Aug 202310:16 amRNSTotal Voting Rights
31st Jul 20231:52 pmRNSDirector/PDMR Shareholding
28th Jul 20237:00 amRNSInterim Results
12th Jul 20231:13 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:58 pmRNSBlock listing Interim Review
3rd Jul 20232:41 pmRNSTotal Voting Rights
26th Jun 20234:39 pmRNSHolding(s) in Company
14th Jun 202310:48 amRNSDirector/PDMR Shareholding
8th Jun 20233:18 pmRNSDirector/PDMR Shareholding
1st Jun 20231:51 pmRNSTotal Voting Rights
22nd May 202310:18 amRNSDirectorate Change
11th May 202311:49 amRNSHolding(s) in Company
10th May 20232:40 pmRNSDirector/PDMR Shareholding
4th May 20231:05 pmRNSResult of AGM
4th May 20237:00 amRNSInterim Management Statement
2nd May 20232:46 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.